Optimizing Reperfusion to Improve Outcomes and Neurologic Function

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

December 31, 2029

Conditions
Acute Ischemic Stroke
Interventions
DRUG

JX10

JX10 is a thrombolytic agent.

DRUG

Placebo

Placebo is being used as the comparator.

Trial Locations (21)

21215

RECRUITING

Corxel Investigational Site, Baltimore

60616

RECRUITING

Corxel Investigational Site, Chicago

74104

RECRUITING

Corxel Investigational Site, Tulsa

75246

RECRUITING

Corxel Investigational Site, Dallas

77030

RECRUITING

Corxel Investigational Site, Houston

Unknown

RECRUITING

Corxel Investigational Site, Blagoevgrad

RECRUITING

Corxel Investigational Site, Baotou

RECRUITING

Corxel Investigational Site, Beijing

RECRUITING

Corxel Investigational Site, Beijing

RECRUITING

Corxel Investigational Site, Guangzhou

RECRUITING

Corxel Investigational Site, Harbin

RECRUITING

Corxel Investigational Site, Kaili

RECRUITING

Corxel Investigational Site, Linfen

RECRUITING

Corxel Investigational Site, Shanghai

RECRUITING

Corxel Investigational Site, Shenyang

RECRUITING

Corxel Investigational Site, Suzhou

RECRUITING

Corxel Investigational Site, Weifang

RECRUITING

Corxel Investigational Site, Xuzhou

RECRUITING

Corxel Investigational Site, Roma

RECRUITING

Corxel Investigational Site, Barcelona

RECRUITING

Corxel Investigational Site, Madrid

Sponsors
All Listed Sponsors
lead

Corxel Pharmaceuticals

INDUSTRY

NCT06990867 - Optimizing Reperfusion to Improve Outcomes and Neurologic Function | Biotech Hunter | Biotech Hunter